Company Overview
XORTX Therapeutics Inc. operates as a late-stage clinical pharmaceutical company focused on the development and commercialization of therapies designed to treat hyperuricemia-related diseases within the Canadian market. The company's primary operational focus lies within the Healthcare sector, specifically the Biotechnology industry, which typically involves high-risk research and development aimed at bringing novel medical treatments to patients. The firm currently holds a market capitalization of $3.00M, with no reported annual revenue or employee count available in public filings. These valuation and scale metrics indicate that XORTX is a micro-cap entity with a very small financial footprint, suggesting it is in an early commercialization phase where revenue generation from its pipeline assets, such as XRx-026 and XRx-008, has not yet materialized to a level that can be disclosed as standard TTM revenue.
Financial Health
The company reports a Net Income (TTM) of $-2,656,304 and an EBITDA of $-2,508,489, while Revenue (TTM) is listed as N/A, indicating that the firm has not yet achieved significant commercial sales to offset its operating expenses. The substantial gap between the reported net income and the near-zero EBITDA reveals a cost structure heavily influenced by non-operating factors, likely interest expenses or other financing costs, rather than core operational inefficiencies. Free Cash Flow stands at $-1,856,310, which signifies that the company is burning cash rapidly to fund its R&D and clinical trial activities, thereby limiting its current financial flexibility and reliance on external capital raises. All three margin metrics—Gross Margin, Operating Margin, and Profit Margin—are recorded at 0.0%, a figure that reflects the absence of realized revenue rather than a failure to control costs on existing sales. On the balance sheet, the company holds $864,514 in cash against $37,287 in debt, resulting in a Debt to Equity ratio of 1.79 which suggests a leveraged position relative to equity, despite the low absolute debt amount. The Current Ratio is 2.10, indicating that the company possesses more than twice the current assets necessary to cover its short-term liabilities, suggesting adequate liquidity for immediate obligations. Return on Equity is -98.0% and Return on Assets is -46.8%, metrics that reveal that the company is currently destroying value per unit of capital employed due to its pre-revenue status and high burn rate.
Valuation Assessment
The company presents a Trailing P/E (TTM) of N/A due to its negative earnings, while the Forward P/E is listed as 0.47, a metric that is mathematically derived from projected earnings and implies an expectation of significant future profitability once the drug candidates reach commercial milestones. The Price to Book ratio is 1.27, indicating that the market values the company at 27% above its net book value, which can be attributed to the intangible value of its intellectual property and pipeline assets rather than tangible assets. The Price to Sales ratio is N/A because there is no revenue data, and the EV/EBITDA stands at -0.72, suggesting that the enterprise value is slightly lower than its EBITDA due to the negative earnings profile and specific capital structure. The 52-week high is $1.41 and the 52-week low is $0.35, placing the current trading price within this volatility range but requiring specific market data to determine the exact percentage position relative to these extremes. The Beta is 0.10, which indicates that the stock exhibits extremely low price volatility relative to the broader market, moving significantly less than the S&P 500 in response to general market fluctuations.
Growth & Income
Revenue Growth (YoY) and Earnings Growth (YoY) are both listed as N/A, reflecting the company's status as a pre-revenue biotech firm that has not yet generated the consistent income streams required to calculate year-over-year growth rates. Because the company is not a dividend payer, there is no Dividend Yield or Payout Ratio to analyze, meaning the firm reinvests all available capital back into its research and development efforts rather than distributing returns to shareholders. This lack of dividend income is typical for late-stage clinical pharmaceutical companies that prioritize funding their Phase III trials and commercial launch over returning capital to investors. Consequently, the overall growth and income profile is characterized by a complete reliance on capital appreciation potential derived from the successful commercialization of its hyperuricemia therapies rather than any current yield or historical earnings expansion.